Hey blasters,
has anyone has been to this ARDS Summit conference last week in Boston where both MSB Head of Pharma Michael S (speaker) and CEO Silviu (Chair) were scheduled to attend and contribute to the scientific program. May have provided clues re MSB ARDS program...
Jadistem both validates MSB efforts in this space and the retained FDA interest in stem cell as a potential therapy for C19 ARDS. Good thing. However I have to agree that it is also an emerging competition getting closer w ph3 kicking-off.
My bet is on MSB getting first to the finish line (EUA or Approval) especially if they are able to commence their confirmatory ph3 program in 2022 given the 40 or so recruiting locations (if I recall) which would expedite recruitment (& commercialisation) along with the initial data form the ph2b/3 trial.
We shall see...
Interesting MSC's Article, page-16
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.28 |
Change
-0.005(0.39%) |
Mkt cap ! $1.478B | |||
| Open | High | Low | Value | Volume |
| $1.29 | $1.31 | $1.27 | $936.9K | 728.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 129997 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.28 | 5874 | 6 |
View Market Depth
| Last trade - 12.28pm 05/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |